Nanexa raises approximately SEK 126.7 million in fully subscribed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AMERICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
Nanexa AB (publ) (”Nanexa” or the “Company”) today announces that the new share issue with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million before transaction costs (the “Rights Issue”) was fully subscribed. Approximately 16.6 percent of the Rights Issue was subscribed for through subscription commitments. In addition to the subscription through subscription commitments, approximately 40.2 percent was subscribed for by the use of subscription rights, and approximately 14.9 percent was subscribed for without subscription rights. The remaining part of the Rights Issue was subscribed for through guarantee commitments from the existing shareholder Rutger Arnhult via M2 Capital Management, and from external investors, including, amongst others, Health Runner and Modelio Equity.
The result of the Rights Issue of 25,347,813 shares is that 4,217,421 new shares, corresponding to approximately 16.6 percent of the Rights Issue, have been subscribed for through subscription commitments. In addition to the subscription through subscription commitments, 10,186,731 shares, corresponding to approximately 40.2 percent of the Rights Issue, have been subscribed for by the use of subscription rights, and 3,769,920 shares, corresponding to approximately 14.9 percent of the Rights Issue, have been subscribed for without subscription rights. The remaining part of the Rights Issue, corresponding to 7,173,741 shares and approximately 28.3 percent of the Rights Issue, have been subscribed for through guarantee commitments from the existing shareholder Rutger Arnhult via M2 Capital Management, and from external investors, including, amongst others, Health Runner and Modelio Equity.
”We appreciate the support from our current shareholders and are delighted to welcome a number of new investors. The share issue secures financing of clearly value-adding activities, especially in ongoing and planned studies. We look forward to the first clinical study results later this year”, said David Westberg, CEO of Nanexa.
Allotment of shares subscribed for without subscription rights has been resolved on in accordance with the established allotment principles. Notice of allotment of shares subscribed for without subscription rights will be sent to those who are subject to such allotment. Payment shall be made in accordance with the instructions on the contract note. Nominee-registered shareholders will receive notice of allotment and payment in accordance with the procedures of each nominee.
Following the Rights Issue, Nanexa’s share capital will increase by SEK 3,280,548 to SEK 6,561,097 and the number of shares will increase by 25,347,813 shares to 50,695,626 shares.
Paid subscribed shares (“BTAs”) will be subject to trading on Nasdaq First North Growth until the Rights Issue has been registered with the Swedish Companies Registration Office and the BTAs have been converted into shares, which is expected to take place around week 29.
ABG Sundal Collier acted as sole global coordinator and bookrunner in connection with the Rights Issue. Advokatfirman Lindahl KB acted as the legal advisor to the Company.
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer to sell or an offer to buy or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal. In a member state within the European Economic Area ("EEA"), securities referred to in the press release may only be offered in accordance with applicable exemptions under Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”).
This press release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release may not be sold in the United States without registration, or without application of an exception from registration, according to the applicable U.S. Securities Act from 1933 (“Securities Act”), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States. The information in this press release may not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction in which the release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would demand additional registration or other actions according to Swedish law. Acts in contrary to this instruction may constitute a crime according to applicable securities laws.
The EU growth prospectus which has been drafted regarding the Rights Issue described in this press release was published by the Company on 11 June 2021. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Sw: Finansinspektionen), which is the competent authority pursuant to the Prospectus Regulation, and is available on the Company’s website, https://www.Nanexa.se/. The approval of the prospectus by the Swedish Financial Supervisory Authority shall not be construed as any kind of support for or endorsement of the Company or the quality of the securities referred to in the prospectus. This release is not a prospectus in accordance with the definition in the Prospectus Regulation as has not been approved by any regulatory authority in any jurisdiction. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the prospectus. Thus, investors are encouraged to review the prospectus in its entirety. This press release constitutes an advertisement in accordance with article 2 k of the Prospectus Regulation. Nanexa has not authorized any offer to the public of shares or rights in any other member state of the EEA than Sweden. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares. An investment decision to acquire or subscribe for shares in the Rights Issue shall only be made based on publicly available information.
To the extent this press release contains forward-looking statements, such statements does not constitute facts and are characterized by words such as “shall”, “expect”, “believe” “assess”, “intend”, “estimate” and similar expressions. Such statements reflect Nanexa’s intentions, views or present expectations or assumptions. Such forward-looking statements are based on Nanexa’s current plans, estimates and projections, which have been made to the best of Nanexa’s ability. However, Nanexa does not assert that these statements will be correct in the future. Forward-looking statements are associated with risks and uncertainties which are difficult to predict and which generally cannot be affected by Nanexa. It should be contemplated that actual events or outcomes may differ materially from what is included or expressed in such forward-looking statements.